DeCure for Autosomal dominant Ehlers-Danlos syndrome, vascular type
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for autosomal dominant Ehlers-Danlos syndrome, vascular type — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutosomal dominant Ehlers-Danlos syndrome, vascular type maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autosomal dominant ehlers-danlos syndrome, vascular type is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
collagen type III alpha 1 chain (COL3A1) — COL3A1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet flcdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6FZW · 2.78 Å · ligand CITRATE ANION (FLC). Experimental structure, not a prediction.
What the evidence adds up to
Vascular Ehlers-Danlos syndrome is an autosomal dominant connective tissue disorder caused by a mutation in type III procollagen. It carries the highest mortality rate among the six types of Ehlers-Danlos syndrome. Patients may present with aneurysm formation or arterial dissection. Because of vessel fragility, operative therapy is reserved for compelling indications where benefit clearly warrants risk, and assessment of that risk remains largely clinical, guided by factors such as response to previous operations and age at first vascular complication. Two case reports from 2017 describe diagnostic and treatment challenges, and a 2023 report details open surgical repair of an infected abdominal aortic aneurysm after aortic dissection in a patient with vEDS. No drug therapy is mentioned in any of these abstracts.
A 2012 review of two patients with symptomatic type IV vascular Ehlers-Danlos syndrome emphasises that operative decisions are guided by clinical judgment rather than controlled evidence. A 2025 review provides a concise overview of the genetic basis, clinical manifestations, diagnostic approaches, and current treatment strategies, but does not report any new trial data, survival figures, or response rates. Across all four abstracts, no quantitative outcomes such as survival or complication rates are given for any intervention.
No randomised trials, no controlled comparisons, and no drug treatments are described in these abstracts. What is missing is any prospective trial design, any patient stratification strategy, and any funding for systematic investigation of medical or surgical management in this rare, high-mortality condition.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Genetics · 1987 · 20 citations
Cardiovascular complications in the Ehlers‐Danlos syndrome with minimal external findings
AbstractEhlers-Danlos syndrome (EDS) is clinically and genetically a heterogeneous disorder of connective tissue. Eleven different types of EDS have been documented, several of which have major cardiovascular complications as part of their clinical manifestations. The purpose of this report is to call attention to a form of EDS with minimal external features but severe internal vascular complications.
Vascular and Endovascular Surgery · 2012 · 8 citations
Varying Presentations in Patients With Symptomatic Type IV Vascular Ehlers-Danlos Syndrome
AbstractEhlers-Danlos syndrome (EDS) represents a group of inheritable connective tissue disorders. Patients with type IV or vascular EDS, autosomal dominant pattern of inheritance, may present with aneurysm formation or arterial dissection. Due to vessel fragility, operative therapy for such disorders has been reserved for compelling indications in which benefit clearly warrants risk, yet assessment of risk is largely clinical with operative decisions guided by factors such as response to previous operations and age at onset of index vascular complications. We present 2 patients with differences in their clinical presentations and outcomes and review the literature with emphasis on operative decision making.
Baylor University Medical Center Proceedings · 2017 · 7 citations · open access
Understanding Vascular-Type Ehlers-Danlos Syndrome and Avoiding Vascular Complications
AbstractVascular-type Ehlers-Danlos syndrome (EDS) is a rare inherited connective tissue disorder caused by a mutation in type III procollagen. It has the highest mortality rate among the six types of EDS. Patients with this syndrome often have typical medical histories and a characteristic physical examination. We present two patients with this rare disorder and highlight the diagnostic and treatment challenges.
Journal of Rare Diseases Research & Treatment · 2025 · 0 citations · open access
Vascular Ehlers-Danlos Syndrome: Current Understanding and Treatment Strategies
AbstractVascular Ehlers-Danlos Syndrome (vEDS) is a rare and severe subtype of Ehlers-Danlos Syndrome (EDS), a group of inherited disorders affecting connective tissue. Unlike other EDS subtypes primarily characterized by joint hypermobility and skin elasticity, vEDS is distinguished by its impact on the vascular system, posing a significant risk of life-threatening complications1. This review aims to provide a concise overview of vEDS, encompassing its genetic basis, clinical manifestations, diagnostic approaches, and current treatment strategies.
Journal of Vascular Surgery Cases and Innovative Techniques · 2023 · 0 citations · open access
Open repair of an infected abdominal aortic aneurysm in a patient with vascular Ehlers-Danlos syndrome
AbstractVascular Ehlers-Danlos syndrome (vEDS) is a rare disorder caused by abnormal type III procollagen molecules. Among other findings, arterial dissection and aneurysms can occur.1-3 Our Supplementary Video (online only) presents the open surgical repair of an isolated infected abdominal aortic aneurysm after aortic dissection in the setting of vEDS. The patient provided written informed consent.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
